Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Total Liabilities (2023 - 2026)

Alto Neuroscience has reported Total Liabilities over the past 4 years, most recently at $32.9 million for Q1 2026.

  • Quarterly results put Total Liabilities at $32.9 million for Q1 2026, changed 0.22% from a year ago — trailing twelve months through Mar 2026 was $32.9 million (changed 0.22% YoY), and the annual figure for FY2025 was $33.5 million, up 28.62%.
  • Total Liabilities reached $32.9 million in Q1 2026 per ANRO's latest filing, down from $33.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $61.1 million in Q3 2023 and bottomed at $16.8 million in Q1 2024.
  • Median Total Liabilities over the past 4 years was $32.9 million (2026), compared with a mean of $33.2 million.
  • The largest annual shift saw Total Liabilities tumbled 66.57% in 2024 before it skyrocketed 96.0% in 2025.
  • Over 4 years, Total Liabilities stood at $16.8 million in 2023, then surged by 55.04% to $26.1 million in 2024, then grew by 28.62% to $33.5 million in 2025, then fell by 1.96% to $32.9 million in 2026.
  • Business Quant data shows Total Liabilities for ANRO at $32.9 million in Q1 2026, $33.5 million in Q4 2025, and $35.4 million in Q3 2025.